Overview
Daiichi Sankyo Co., Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, it has businesses in Japan and internationally, with oncology and cardiovascular medicines among its defining product areas. Its products include the cancer treatment Enhertu and the anticoagulant Lixiana.[1][2][3]
The company states its purpose as contributing to quality of life around the world and its mission as creating innovative pharmaceuticals that address diverse medical needs. For the fiscal year ended March 2025, Daiichi Sankyo reported revenue of ¥1,886.3 billion and approximately 19,800 employees; the group had a presence in 32 countries and regions.[4][5] [1][2][3][4][5]
Products & services
Daiichi Sankyo’s prescription portfolio includes ENHERTU (trastuzumab deruxtecan), a HER2-directed antibody–drug conjugate (ADC) used for certain breast, gastric and lung cancers, and DATROWAY (datopotamab deruxtecan), a TROP2-directed ADC used for certain breast cancers. Both use the company’s DXd technology, which links a targeting antibody to a topoisomerase-I inhibitor payload. VANFLYTA (quizartinib) is a FLT3 inhibitor for FLT3-ITD-positive acute myeloid leukemia. Indications vary by country.[6][7][8]
Other medicines include LIXIANA (edoxaban), an oral factor Xa inhibitor used to prevent stroke in certain patients with atrial fibrillation and to treat venous blood clots; TARLIGE (mirogabalin) for neuropathic pain; NILEMDO/NEXLETOL (bempedoic acid) for lowering LDL cholesterol; and INJECTAFER (ferric carboxymaltose), an intravenous iron treatment. In the fiscal year ended March 2025, ENHERTU generated ¥651.4 billion, approximately 34.5% of consolidated revenue.[9][10][11][12][13]
The group also supplies vaccines in Japan and, through Daiichi Sankyo Healthcare, consumer products spanning over-the-counter medicines, skin care and oral care. Consumer brands include LOXONIN S pain relievers and LULU cold remedies.[14][15][16][17] [6][7][8][9][10][11][12][13][14][15][16][17]
Geographic presence
Daiichi Sankyo is headquartered in Tokyo, Japan, and operates across Japan, the United States, Europe and other international markets, including Asia and South and Central America. Its U.S. group companies include Daiichi Sankyo, Inc. in Basking Ridge, New Jersey, and American Regent in Shirley, New York.[1][18][19]
For the fiscal year ended March 2025, overseas revenue was ¥1,302.5 billion, or approximately 69% of consolidated revenue of ¥1,886.3 billion; the remaining approximately ¥583.8 billion was attributable to Japan. The company reported 19,765 employees worldwide at fiscal year-end.[20] [19][1][18][20]
Business segments
Daiichi Sankyo reports **Pharmaceuticals as its sole reportable segment**. It also discloses revenue by business unit, which provides a more detailed view of its operations but does not represent additional reportable segments.[21][22]
For the nine months ended December 31, 2024, the approximate shares of consolidated revenue were **Oncology Business 29%**, covering oncology medicines sold across multiple regions; **Japan Business 25%**; **EU Specialty Business 13%**, including products such as Lixiana and Nilemdo/Nustendi; **ASCA Business 12%**, covering Asia, South and Central America; **American Regent 9%**, including iron therapies and generic injectables; and **Daiichi Sankyo Healthcare 5%**, shown separately from Japan Business. These are interim business-unit revenue shares, not full-year reportable-segment percentages; the listed units do not account for all consolidated revenue.[22][23][24] [22][23][24][21]
Company history
Daiichi Sankyo traces its origins to Sankyo Shoten, founded in 1899, and Arsemin Shokai, founded in 1915 and renamed Daiichi Pharmaceutical in 1918. Among the predecessor companies’ notable medicines were Sankyo’s pravastatin, launched in Japan in 1989, and Daiichi’s levofloxacin, introduced in Japan in 1993.[25][26]
Sankyo and Daiichi Pharmaceutical established Daiichi Sankyo as a joint holding company in September 2005; the integrated pharmaceutical company began operations in April 2007.[27] Daiichi Sankyo acquired a majority stake in Indian drugmaker Ranbaxy in 2008, and Ranbaxy subsequently merged with Sun Pharma in 2015.[28][29] In 2019, Daiichi Sankyo entered a global development and commercialization partnership with AstraZeneca for the cancer medicine trastuzumab deruxtecan, later approved in the United States as Enhertu.[30][31] [25][26][27][28][29][30][31]
Sources
- www.daiichisankyo.com[1]
- www.daiichisankyo.com[2]
- www.daiichisankyo.com[3]
- www.daiichisankyo.eu[4]
- www.daiichisankyo.com[5]
- www.daiichisankyo.com[6]
- www.daiichisankyo.com[7]
- www.accessdata.fda.gov[8]
- www.ema.europa.eu[9]
- www.daiichisankyo.co.jp[10]
- www.ema.europa.eu[11]
- www.accessdata.fda.gov[12]
- www.daiichisankyo.com[13]
- www.daiichisankyo.co.jp[14]
- www.daiichisankyo.co.jp[15]
- www.daiichisankyo-hc.co.jp[16]
- www.daiichisankyo-hc.co.jp[17]
- www.daiichisankyo.com[18]
- DAIICHI SANKYO CO LTD — Presentation (2025 Q 3)
- www.daiichisankyo.com[20]
- www.daiichisankyo.com[21]
- www.daiichisankyo.com[25]
- www.daiichisankyo.com[26]
- www.daiichisankyo.com[27]
- www.daiichisankyo.com[28]
- www.daiichisankyo.com[29]
- www.daiichisankyo.com[30]
- www.accessdata.fda.gov[31]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore DAIICHI SANKYO CO LTD in Finbar ↗